Drugs / HZN-457
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05565768 | Nov 2022 → Aug 2023 | — | Horizon Therapeutics Ireland DAC | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-12-08 | Arrowhead Pharmaceuticals | Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout arrowheadpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HZN-457 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05565768 ↗ |
| Route | Subcutaneous | “subcutaneous administration” NCT05565768 ↗ |